FDA Breakthrough Device Designation
Turning Medical Imaging into
ActionableAI Intelligence
Advancing the Future of Endoluminal Diagnostics and Therapeutics.
Incubated & Supported By
Our Vision
GI Cancers
Global Health CrisisGlobal Burden
1 in 4
Cancer cases
1 in 3
Cancer deaths
Most patients are diagnosed only when symptoms emerge often at advanced, unresectable stages.
The Diagnostic Gap
Detection still depends heavily on human perception under intense time pressure leading to missed lesions and delayed intervention.
Early Gastric Cancer
upto 18%
lesions indicative of early gastric cancer missed
Early Esophageal Cancer
upto 25%
lesions indicative of early esophageal cancer missed
Why Early Detection Matters
From Late Stage to Early Cure.
When identified early, GI cancers are highly treatable through minimally invasive endoscopic procedures resulting in significantly better prognoses and reduced healthcare burden.
20%
5-Year Survival With late-stage detection
90%
5-Year Survival With early detection
Regulatory Status
CDSCO Test License
Form MD 13
Granted - July 2024
2x
FDA Breakthrough Device Designations
In The News
BusinessWire India
RNT Health Insights Private Limited Receives FDA Breakthrough Device Designation for Early Gastric Cancer Detection Tool
Fortune India
Pfizer offers grant and incubation support to 14 Indian health-tech startups under 'INDovation Program'
Economic Times
Nikhil Kamath unveils first 15 grantees of his WTFund
BioSpectrum India
RNT Health Insights receives second US FDA breakthrough device designation for oesophageal cancer detection tool
MedTech Innovator
20 Startups Named to MedTech Innovator Asia Pacific Accelerator
Economic Times